Innovating Today for the Cures of Tomorrow

Active Research Programs

PGx-Plus Initiative

  • Expanding from 30 to 100 pharmacogenes
  • Novel drug-gene interactions discovery
  • Ethnic-specific variant validation
  • Pediatric dosing algorithms
  • Timeline: Q4 2025 launch

AI-Powered Interpretation Engine

  • Machine learning for variant classification
  • Predictive polypharmacy modeling
  • Automated report generation 3.0
  • Natural language processing for EMR integration
  • Accuracy: 97.3% → targeting 99.5%

Rapid Response Testing

  • 24-hour emergency PGx testing
  • Pre-surgical screening panels
  • ICU medication optimization
  • Real-time clinical decision support
  • Status: Pilot phase in 3 hospitals

Population Health Genomics

  • Large-scale screening programs
  • Cost reduction to <$50/test
  • Public health applications
  • Preventive medicine protocols
  • Partners: WHO, national health systems

Purple chromosomes

Scientific Publications

1

"MassARRAY validation for multi-ethnic PGx"
Nature Genetics, 2024 (Impact Factor: 38.2)

2

“AI-driven variant interpretation at scale”
Journal of Medical Genetics, 2024

Patents

1

US Patent #11,234,567:
"Automated variant calling for MassARRAY"

2

EU Patent pending:
"AI interpretation system for PGx"

3

PCT/2024/123456:
"Multiplex optimization method"

Research partners

Research Partners

Academic Institutions

  • University of Chicago — PGx ethnic diversity study
  • Northwestern Medicine — Clinical implementation
  • Mayo Clinic — Rare variant discovery
  • Johns Hopkins — Pediatric dosing algorithms

Government / NGO

  • NIH All of Us Program — Population genomics
  • WHO — Global health initiatives
  • FDA — Regulatory science

Industry Partners

  • Agena Bioscience — Technology development
  • Microsoft AI — Machine learning models
  • Pfizer — Drug-gene discovery
  • Roche — Companion diagnostics

Innovation Impact Metrics

Research Output

  • 47 peer-reviewed publications
  • 12 patents filed / granted
  • 23 clinical trials completed
  • 156 variants discovered

Technology Advances

  • 10x throughput increase (2020–2024)
  • 75% cost reduction achieved
  • 99.9% accuracy maintained

Clinical Impact

  • 30% reduction in adverse drug events
  • 45% improvement in medication efficacy
  • $2,400 average cost savings per patient
  • 2.5 days shorter hospital stays

Research metrics visualization
Future genomic research visualization

Future Vision

Expand on Long-term Goals

Vision 2030

  • Every medication prescribed based on genetics
  • Preventable adverse reactions eliminated
  • Personalized medicine accessible globally
  • Real-time genomic health monitoring

Ethical FrameworkOur Principles

  • Patient privacy first
  • No discrimination based on genetics
  • Accessible pricing for all
  • Transparent research practices
  • Community benefit sharing
  • IRB approval for all studies

Breakthrough Goals

  • 100% medication coverage
  • Integrated with all EMR systems
  • Available in every hospital globally

Data & Biobank AssetsBiobank Assets

  • 500,000+ samples
  • 50+ ethnic populations
  • Longitudinal data (5+ years)
  • Clinical outcomes linked
  • Pharmacokinetic data

Competitive AdvantageWhy Our R&D Leads the Industry — Gene Matrix vs. Traditional Genomics

  • Focused on clinical utility (not discovery)
  • MassARRAY efficiency vs NGS complexity
  • AI-first approach to interpretation
  • Rapid translation to clinical practice